Cerebrospinal fluid gastrin releasing peptide in the diagnosis of leptomeningeal metastases from small cell carcinoma

Cancer

Volumn 91, Issue 11, 2001, Pages 2122-2126

  Castro, Michael P ^a   McDonald, Tom J ^b   Qualman, Stephen J ^c   Odorisio, Thomas M ^d  

^a Glens Falls Cancer Center ^*  (United States)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

Bombesin; Cerebrospinal fluid (CSF) tumor markers; Gastrin releasing peptide (GRP); Leptomeningeal metastases; Malignant meningitis; Small cell carcinoma

Indexed keywords

GASTRIN RELEASING PEPTIDE; TUMOR MARKER;

ADULT; ARTICLE; BRAIN METASTASIS; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CYTOLOGY; HUMAN; LUMBAR PUNCTURE; MALE; MENINGITIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SMALL CELL CARCINOMA;

CARCINOMA, SMALL CELL; DIAGNOSIS, DIFFERENTIAL; GASTRIN-RELEASING PEPTIDE; HUMANS; LUNG NEOPLASMS; MALE; MENINGEAL NEOPLASMS; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 0035370430     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010601)91:11<2122::AID-CNCR1240>3.0.CO;2-8     Document Type: Article

References (22)

1. Selawry OS, Hansen HH. Lung cancer. In: Holland JF, Frei E, editors. Cancer medicine. 2nd ed. Philadelphia: Lea and Feibiger, 1982:1709-44.
2. Primack. The production of markers in bronchogenic carcinoma. In: Strauss M, editor. Lung cancer. New York: Grune Stratton.
3. Okusaka T, Eguchi K, Kasai T, Kurata T, Yamamoto N, Ohe Y, et al. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res 1997;3:123-7.
4. Miyake Y, Kodama T, Yamaguchi K. Pro-gastrin-releasing peptide (31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1994;54:2136-40.
5. Takada M, Kusunoki Y, Masuda N, Matui K, Yana T, Ushijima S, et al. Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. Br J Cancer 1996;73: 1227-32.
6. Sunaga N, Tsuchiya S, Minato K, Watanabe S, Fueki N, Hoshino H, et al. Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer. Oncology 1999;57:143-8.
7. Yamaguchi K, Koh-ichi I, Maruno K, Miyake Y, Shimosato Y, Abe K. Lung cancer and autocrine growth factors. Fifth World Congress on Lung Cancer. Chest 1989;96(Suppl):29S-31S.
8. Holst JJ, Hansen M, Bork E, Schwartz TW. Elevated plasma concentrations of C-flanking gastrin-releasing peptide in small-cell lung cancer. J Clin Oncol 1989;7:1831-8.
9. Maruno K, Yamaguchi K, Abe K, Suzuki M, Saijo N, Mishima Y, et al. Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1989;49:629-32.
10. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985;313:745-7.
11. Johnson BE, Kelley MJ. Biology of small cell lung cancer. Oncology (Huntingt) 1998;12(1 Suppl 2):11-4,.
12. Kelley MJ, Linnoila RI, Avis IL, Georgiadis MS, Cuttitta F, Mulshine JL, et al. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 1997;112:256-61.
13. Pedersen AG, Becker KL, Bach F, Snider RH, Gazdar AF, Sorensen PS, et al. Cerebrospinal fluid bombesin and calcitonin in patients with central nervous system metastases from small-cell lung cancer. J Clin Oncol 1986;4:1620-7.
14. McDonald TJ, Christofi FL, Brooks BD, Barnett W, Cook MA. Characterization of content and chromatographic forms of neuropeptides in purified nerve varicosities prepared from guinea pig myenteric plexus. Regul Pept 1988;21:69-83.
15. Anderson NE, Rosenblum MK, Graus F, Wiley RG, Posner JB. Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer. Neurology 1988;38:1391.
16. Carney DN, Baum PA, Gazdar AF. Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell lung carcinoma. Proc Natl Acad Sci USA 1981;78:3185-98.
17. Rodesch G, Van Bogaert P, Mavroudakis N, Parizel PM, Martin JJ, Segebarth C, et al. Neuroradiologic findings in leptomeningeal carcinomatosis: the value interest of gadolinium enhanced MRI. Neuroradiology 1990;32:26-32.
18. Pedersen AG, Hammer M, Hansen M, Sørensen PS. Cerebrospinal fluid vasopressin as a marker of central nervous system metastases from small-cell bronchogenic carcinoma. J Clin Oncol 1985;3:48-53.
19. Hansen M, Pedersen AG. Tumor markers in patients with lung cancer. Chest 1986;89(4 Suppl):219S-24S.
20. Pedersen AG, Bach FW, Nissen M, Bach F. Creatine kinase BB and beta-2-microglobulin as markers of CNS metastases in patients with small-cell lung cancer. J Clin Oncol 1985;3: 1364-72.
21. Pedersen AG, Hansen M, Hummer L, Rogowski P. Cerebrospinal fluid ACTH as a marker of central nervous system metastases from small cell carcinoma of the lung. Cancer 1985;56:2476-80.
22. Kamata K, Uchida M, Takeuchi Y, Takahashi E, Sato N, Miyake Y, et al. Increased serum concentrations of progastrin-releasing peptide in patients with renal dysfunction. Nephrol Dial Transplant 1996;11:1267-70.